Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine

Hadassah Medical Organization100 enrolled

Overview

The purpose of this study is to compare the reliability and validity of a new device with standard methods for diagnosing between amniotic fluid leakage due to premature rupture of the membranes (PROM) and urine.

Pregnant women sensing wetness and arriving to the delivery room with suspect PROM will use a self-testing device to test whether the wetness is caused by amniotic fluid leakage or urinary incontinence. Clinical evaluation will be performed to all pregnant women using standard clinical tests. The results of the standard clinical tests will be compared to the women's reading of the self-testing device results. Sensitivity and specificity of the device evaluation will be calculated.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

100

Conditions

Amniotic Fluid Leakage

Interventions

BirthSignDEVICE

When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Pregnant women age 18 years and older attending delivery room. 2. Stage of gestation: pregnancy between 16 and 42 weeks of gestation. 3. Able and willing to read and sign an informed consent document. Exclusion Criteria: Subjects will be excluded from the study if any of the following will be present: 1. Prior use of any amniotic fluid detection test. 2. Use of vaginal douching apparatus (such as a vaginal bulb syringe) or vaginal products such as creams or gels within the past 24 hours. 3. Vaginal bleeding or spotting or excess abnormal vaginal discharge within the past 24 hours. 4. Sexual intercourse within the past 24 hours. 5. Confirmed diagnosis of any vaginal infection within the past 7 days. 6. Use of vaginal products or antibiotic treatments that reduce bacterial population or use of medications such as tamoxifen that reduce estrogen levels or antihistamines that dry mucous membranes within the past 7 days.. 7. Patients unable or unwilling to participate. 8. Patients in active labor (or with regular contractions).

Locations (1)

Hadassah Medical Organization

Jerusalem, Israel

Outcomes

Primary Outcomes

Presence / absence of stains comparing to a known color index printed on the product

Presence / absence of a blue-green stain and / or brown-red stain as yielded by the device and observed by the woman.

Time frame: 12 hours

Secondary Outcomes

Presence / absence of stains comparing to a known color index printed on the product

Presence / absence of a blue-green stain and / or brown-red stain as yielded by the device and observed by the clinician and a measurement of patient comfort while using the device, reading the results and clarity of instructions.

Time frame: 12 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.